Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from enGene Holdings ( (ENGN) ).
enGene announced that President and CEO Ron Cooper will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, with a live webcast and 90-day archive available via the company’s investor relations website. The appearance underscores enGene’s efforts to raise its visibility within the biotech investment community as it advances its lead bladder cancer program and proprietary non-viral genetic medicine platform, potentially reinforcing investor interest and strategic positioning in the competitive genetic therapies landscape.
The most recent analyst rating on (ENGN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large operating losses, and significant cash burn). Technicals are supportive due to a strong uptrend, but momentum appears overextended. The recent $130M financing improves funding runway, partially offsetting the weak fundamentals, while valuation remains constrained by a negative P/E and no dividend support.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines, with a focus on delivering therapeutics to mucosal tissues and other organs to address diseases with high unmet clinical needs. Its lead candidate, detalimogene voraplasmid (detalimogene, formerly EG-70), targets non-muscle invasive bladder cancer and is being studied in the LEGEND Phase 2 trial, including a pivotal cohort in high-risk, BCG-unresponsive carcinoma in situ patients, and is based on the company’s proprietary Dually Derivatized Oligochitosan (DDX) delivery platform.
Average Trading Volume: 1,307,197
Technical Sentiment Signal: Buy
Current Market Cap: $669.8M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.